Twins: Jesy Nelson’s Children Battling Spinal Muscular Atrophy
What the data shows
What happens when twins are diagnosed with a debilitating condition like Spinal Muscular Atrophy (SMA)? This question is at the forefront of discussions surrounding Jesy Nelson’s twins, Emma and Bartosz, who both suffer from this severe genetic disorder. Emma was diagnosed in 2024, while Bartosz received his diagnosis in 2021. Their condition has highlighted the critical need for early screening and intervention.
Emma and Bartosz have SMA type 1, the most severe form of the disease, which can lead to significant mobility issues. Unfortunately, both children were diagnosed late, contributing to the likelihood of lifelong mobility challenges. In the UK, it is estimated that 33 babies each year may require a wheelchair due to similar late diagnoses of SMA.
The Scottish government has taken steps to address this issue by announcing that all babies will be screened for SMA as part of the NHS newborn blood spot test. This initiative is particularly significant as the UK has been identified as a global outlier in newborn SMA screening, with only 46 countries, including the US and nearly three-quarters of Europe, currently implementing such measures.
Emma and Bartosz have received the gene therapy Zolgensma through the NHS, which has the potential to halt the progression of SMA and can eradicate it if administered early enough. This treatment represents a beacon of hope for families affected by this condition, as it can significantly improve quality of life.
Jesy Nelson, the mother of the twins, has expressed her gratitude for the support received from other families facing similar challenges. “We know how you feel,” said Paola and Rhys Davie, parents of children with SMA, offering solidarity to Nelson. Urszula, another parent, empathized, stating, “I’m sorry you’re going through this. I remember how overwhelming it felt at the beginning.” Such sentiments underscore the emotional toll that SMA takes on families.
Paola, reflecting on the situation, remarked, “It’s awful to think that if I’d decided to give birth in Italy, we probably wouldn’t be having this conversation.” This highlights the disparities in healthcare systems and the critical importance of timely diagnosis and treatment.
As the NHS prepares for the projected rollout of SMA screening in England by 2031, the focus remains on ensuring that all newborns have access to early detection and treatment options. The journey for Emma and Bartosz continues, with their family navigating the complexities of SMA while advocating for better healthcare practices.
While the future holds promise with advancements in screening and treatment, uncertainties remain. Details remain unconfirmed regarding the full impact of these initiatives on the lives of children diagnosed with SMA. However, the conversation around early screening and the experiences of families like Jesy Nelson’s is crucial in shaping a more informed and supportive healthcare landscape.